Clinical trials
Metastatic HER2-Negative Breast Carcinoma clinical trials
Below are recruiting metastatic her2-negative breast carcinoma clinical trials, each written for real people, not researchers. We’re tracking 102 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06058377RecruitingPhase 3
Adding immunotherapy to chemo for stage II-III breast cancer
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy works better than chemo alone for people with hormone receptor positive, HER2 negative breast cancer that is stage II or III and has a high-risk genetic score (MammaPrint High Risk 2).
Birmingham, AlabamaAges 18 years+ - NCT07391774RecruitingPhase 3
Hormone therapy with or without chemo for early breast cancer
This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.
Jonesboro, ArkansasAges 18 years+ - NCT06764940RecruitingPhase 2
Utidelone and capecitabine for HER2-negative breast cancer with brain metastases
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
Duarte, CaliforniaAges 18 years+ - NCT06382948RecruitingPhase 3
Elacestrant and everolimus for ESR1-mutant advanced breast cancer
This trial tests a new combination of two oral targeted therapy pills (elacestrant and everolimus) for people with a specific type of advanced breast cancer. It is for those whose cancer has an ESR1 mutation and has stopped responding to CDK4/6 inhibitors and hormone therapy.
InnsbruckAges 18 years+ - NCT06120283RecruitingPhase 1
Testing a new drug for breast cancer and other solid tumors
This trial tests a new oral drug (BGB-43395) alone or with other treatments for people with advanced breast cancer or other solid tumors that depend on CDK4. It aims to find safe doses and see if the drug helps shrink tumors or slow growth.
Denver, ColoradoAges 18 years+ - NCT07631052RecruitingPhase 2
Low-dose Capecitabine for High-risk Early Breast Cancer
This study tests whether a low-dose chemotherapy pill called capecitabine can help prevent breast cancer from coming back in patients whose cancer shows signs of remaining disease (called MRD) despite standard treatment. The trial focuses on hormone-receptor-positive, HER2-negative breast cancers.
Toronto, OntarioAges 18 years+ - NCT07544056RecruitingPhase 2/Phase 3
BEBT-209 Plus Chemotherapy for Triple-Negative Breast Cancer
This study tests a new drug called BEBT-209 combined with chemotherapy (carboplatin and gemcitabine) in women with advanced triple-negative breast cancer that has spread or cannot be surgically removed. The goal is to see if this combination can slow or stop cancer growth better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT06525766RecruitingPhase 2
Adaptive capecitabine therapy for metastatic ER+ HER2− breast cancer
This trial tests whether adjusting the dose of the oral chemotherapy capecitabine over time can control metastatic breast cancer that is estrogen-receptor positive (ER+) and HER2−. It is designed for patients who are starting capecitabine or have just started it, and the study will monitor blood changes and tumor response closely.
Scottsdale, ArizonaAges 18 years+ - NCT07602907RecruitingPhase 2
Low-dose paclitaxel with immunotherapy for advanced HER2-negative breast cancer
This trial tests a combination of low-dose oral paclitaxel (a chemotherapy pill taken regularly) plus immunotherapy to treat advanced breast cancer that doesn't have high levels of HER2 protein. The goal is to slow or shrink tumors while managing side effects better than traditional high-dose chemotherapy.
Hangzhou, ZhejiangAges 18 years+ - NCT05512364RecruitingPhase 3
Elacestrant for ER-positive, HER2-negative breast cancer with ctDNA relapse
This trial tests whether elacestrant can help stop or delay breast cancer coming back in people whose blood test shows “ctDNA relapse” after early breast cancer treatment. It’s meant for hormone receptor–positive, HER2-negative breast cancer patients who are already taking hormone (endocrine) therapy and have no visible spread on scans.
AnderlechtAges 18 years+ - NCT06176261RecruitingPhase 2
Datopotamab deruxtecan for breast cancer with brain spread
This trial tests a new drug called datopotamab deruxtecan for people with HER2-negative breast cancer that has spread to the brain. It looks at how well the drug works against brain metastases.
Miami, FloridaAges 18 years+ - NCT06839560RecruitingPhase 2
Immunotherapy plus chemotherapy and radiation for advanced breast cancer with brain metastases
This trial tests a combination of a PD-L1 inhibitor with a low-dose chemotherapy regimen and either immediate or delayed radiation therapy for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this approach helps shrink brain tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06534125Recruiting
Acupuncture to prevent joint pain from hormone therapy in Black women
This study tests whether acupuncture can prevent joint pain caused by a common hormone therapy pill (aromatase inhibitor) in Black women who have finished treatment for early-stage breast cancer.
Atlanta, GeorgiaAges 18 years+ - NCT06450873RecruitingPhase 2
Turkey tail mushroom before breast cancer surgery
This trial tests whether taking a turkey tail mushroom supplement before breast cancer surgery can help the immune system fight the cancer. It is for post-menopausal women with a common type of breast cancer (ER-positive, HER2-negative) that is growing at a moderate or faster rate (Ki-67 score of 10% or more).
Scottsdale, ArizonaAges 18 years+ - NCT06026657RecruitingPhase 1/Phase 2
NK cells with or without naxitamab for GD2-positive breast cancer
This trial tests a new treatment using immune cells called NK cells combined with chemotherapy (gemcitabine) and possibly naxitamab for people with a certain type of advanced breast cancer that has spread. It aims to see if this approach can help when standard treatments have stopped working.
Columbus, OhioAges 18 years+ - NCT06042569RecruitingPhase 2
Lower-dose chemo for older women with HER2-negative breast cancer
This trial tests whether a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) works well for women 65 and older with early-stage HER2-negative breast cancer. The goal is to maintain effectiveness while reducing side effects in this group.
Duarte, CaliforniaAges 65 years+ - NCT04985266RecruitingPhase 2
Watch blood DNA for early breast cancer return, then add palbociclib
This study checks for early signs that ER-positive, HER2-negative breast cancer may be coming back by testing your blood for cancer DNA. If signs are found, it tests whether adding palbociclib plus fulvestrant works better than standard hormone therapy alone to prevent recurrence.
AngersAges 18 years+ - NCT06418594RecruitingPhase 2
Drug combo for HER2-negative breast cancer brain metastasis
This trial tests a combination of two drugs (adebrelimab and apatinib) plus chemotherapy for women with HER2-negative breast cancer that has spread to the brain. It aims to see if this treatment can help shrink or control brain tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05305924RecruitingPhase 2
Fulvestrant plus abemaciclib for ER+, HER2− advanced breast cancer
This Phase 2 study tests whether adding abemaciclib to fulvestrant can slow or shrink ER-positive, HER2-negative metastatic breast cancer. It is mainly for people whose cancer has progressed despite prior treatment with a CDK4/6 inhibitor and an aromatase inhibitor.
Houston, TexasAges 18 years+ - NCT06179303RecruitingPhase 2
Imaging to predict response to abemaciclib for advanced breast cancer
This trial tests if a special PET scan can predict how well the drug abemaciclib works for people with advanced hormone receptor-positive, HER2-negative breast cancer. If you qualify, you would receive abemaciclib and have imaging scans to see if your cancer responds.
St Louis, MissouriAges 18 years+ - NCT07112053RecruitingPhase 2
Vaccine with hormone therapy or chemo for advanced breast cancer
This trial tests a vaccine (STEMVAC) given with your standard hormone therapy or chemotherapy. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer who are already on certain treatments. The goal is to see if adding the vaccine can help control the cancer better.
Seattle, WashingtonAges 18 years+ - NCT06516289RecruitingPhase 2
Neoadjuvant treatment for BRCA-mutated HER2-negative breast cancer
This trial tests a combination of two oral medications (HRS-1167 and famitinib) with or without an immunotherapy drug (camrelizumab) before surgery for women with a BRCA gene mutation and HER2-negative breast cancer. It aims to see if these drugs can shrink tumors before surgery.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Birmingham, AlabamaAges 18 years+ - NCT06705127RecruitingPhase 2
Radiation, chemo, and immunotherapy for HR+ breast cancer
This trial tests if giving radiation first, then chemo with an immunotherapy drug called Toripalimab, can help treat a certain type of breast cancer that has not spread to other organs. It is for people with hormone receptor positive, HER2 negative breast cancer that is growing fast.
Hangzhou, ZhejiangAges 18–75
Hear when a new Metastatic HER2-Negative Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Metastatic HER2-Negative Breast Carcinoma trials by city
Studies with a site in or near these metro areas.
Metastatic HER2-Negative Breast Carcinoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for metastatic her2-negative breast carcinoma?
- Yes. Clin2 currently lists 102 recruiting metastatic her2-negative breast carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic her2-negative breast carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic her2-negative breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.